+44 (0) 1698 534002
Contact

News

Investment in Echo 650 increases assay ready plate capabilities

18 January 2022

BioAscent has invested in a new Echo 650 Series Acoustic Liquid Handler and Access Workstation to support the automation...

Read more

BioAscent granted Controlled Drug Licence

13 January 2022

BioAscent has been granted a Controlled Drug Licence, allowing the company to store and test scheduled substances on beh...

Read more

New resistance-busting antibiotic combination could extend the use of 'last-resort' antibiotics

14 December 2021

Working in collaboration with teams at the University of Oxford and the Pivot Park Screening Centre as part of the Europ...

Read more

BioAscent reports third year of high double-digit growth

09 December 2021

BioAscent is forecasting another year of significant growth, projecting revenue of £6.8m/€9.1m in 2021. This third conse...

Read more

Lighthouse Lab in Glasgow recognised at THE Awards

03 December 2021

The University of Glasgow's Lighthouse Laboratory project has won the Knowledge Exchange/Transfer Initiative of the...

Read more

BioAscent’s compound management services prove stellar success with biotech companies

21 October 2021

BioAscent has reported a 50% increase in demand from biotech and “virtual” biotech companies for its outsourced compound...

Read more

BioAscent works with University of Edinburgh to form a unique set of compounds

24 September 2021

BioAscent worked closely with Edinburgh Cancer Research Centre (ECRC) at the University of Edinburgh to purchase a set o...

Read more

BioAscent invests in second Biacore 8K machine to meet growing customer demand for expert SPR services

24 September 2021

BioAscent has invested in a second Biacore 8k SPR System, further enhancing its biophysical assay development and screen...

Read more

Triathlon preparation during a pandemic: A personal challenge

31 August 2021

Stuart McElroy, Director of Biosciences at BioAscent will be undertaking the 2021 European Sprint Distance Triathlon Cha...

Read more

Dr Phil Jones presents at BOS Virtual 2021

10 August 2021

BioAscent’s Chief Scientific Officer, Dr Phil Jones, joined industry colleagues to discuss the integrated drug discovery...

Read more

Integrated Drug Discovery

Science-led drug discovery

Compound Management

Connecting and accelerating your drug discovery

Medicinal Chemistry

Proven expertise in design and synthesis

In Silico Discovery

Accelerating drug design with computational expertise

Discovery Biology

Screening expertise across target classes

Get in Touch

Let's talk about how we can maximise your drug discovery success.

Contact